PLYX
Polaryx Therapeutics, Inc.
2.10$
+0.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Polaryx Therapeutics, Inc. (PLYX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -1.4 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|
| -1.3 | -0.9 | -0.7 | -0.9 | -0.9 | -1.5 | -2.1 | -1.4 | -5.8 | |
| 0.0 | 0.1 | 4.5 | 0.1 | 0.1 | 0.1 | 0.5 | 0.0 | 0.6 | |
| -0.6 | -0.2 | -0.1 | 0.0 | 0.4 | -0.1 | -0.4 | 0.2 | 0.2 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | |
| 0.0 | 2.8 | 0.3 | 0.0 | 3.3 | 0.9 | 0.0 | 9.8 | 14 | |
| -1.3 | 1.9 | -0.5 | -0.9 | 2.4 | -0.6 | -2.1 | 8.5 | 8.2 | |
| -1.3 | -0.9 | -0.7 | -0.9 | -0.9 | -1.5 | -2.1 | -1.4 | -5.8 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.